ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Courier Capital LLC

Courier Capital LLC grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 33.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,000 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. Courier Capital LLC’s holdings in ImmunityBio were worth $107,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in ImmunityBio by 43.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company’s stock valued at $47,000 after purchasing an additional 2,844 shares during the last quarter. Meridian Management Co. bought a new position in shares of ImmunityBio during the fourth quarter valued at approximately $46,000. Private Advisor Group LLC acquired a new stake in shares of ImmunityBio during the 4th quarter worth approximately $53,000. Russell Investments Group Ltd. lifted its holdings in shares of ImmunityBio by 408.3% in the 4th quarter. Russell Investments Group Ltd. now owns 14,766 shares of the company’s stock worth $74,000 after purchasing an additional 11,861 shares during the last quarter. Finally, Copperwynd Financial LLC acquired a new position in ImmunityBio during the 4th quarter valued at approximately $79,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler increased their target price on ImmunityBio from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Monday, April 29th.

ImmunityBio Price Performance

Shares of IBRX stock traded down $0.22 during trading hours on Friday, reaching $6.32. The stock had a trading volume of 5,892,415 shares, compared to its average volume of 5,608,891. The firm has a 50-day simple moving average of $6.89 and a 200-day simple moving average of $5.43. The firm has a market capitalization of $4.37 billion, a PE ratio of -6.00 and a beta of 1.03. ImmunityBio, Inc. has a twelve month low of $1.25 and a twelve month high of $10.53.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. On average, equities analysts anticipate that ImmunityBio, Inc. will post -0.75 earnings per share for the current year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.